M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Liposomal amphotericin B
Drug: Voriconazole

First Posted Date: 2007-01-05

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT00418951

Locations: 🇺🇸
The University of Texas M D Anderson Cancer Center, Houston, Texas, United States

Gliogene: Brain Tumor Linkage Study

Conditions: Brain Tumor
Glioma

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-01-05

Last Posted Date: 2020-12-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 17080

Registration Number: NCT00418899

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇮🇱
The Danek Gertner Institute, Tel Hashomer, Israel
🇸🇪
Umeå University Hospital, Umeå, Sweden

and more 12 locations

Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning

Phase 3

Terminated

Conditions: Brain Tumor

Interventions: Drug: SR Methylphenidate
Drug: IR Methylphenidate
Drug: Modafinil

First Posted Date: 2007-01-05

Last Posted Date: 2020-09-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT00418691

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients

Phase 2

Terminated

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: Imatinib Mesylate (IM)
Drug: TALL-104 cells

First Posted Date: 2006-12-25

Last Posted Date: 2014-06-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00415909

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

Phase 2

Terminated

Conditions: Leukemia

Interventions: Biological: Peptide Vaccine (PR1 Peptide)
Drug: Imatinib
Drug: Peginterferon alfa-2b
Drug: GM-CSF

First Posted Date: 2006-12-25

Last Posted Date: 2018-08-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00415857

Locations: 🇺🇸
UT MD . Anderson Cancer Center, Houston, Texas, United States

Respiratory Tumor and Normal Tissue Motion

Completed

Conditions: Lung Cancer
Abdominal Cancer

Interventions: Procedure: Motion CT Scans

First Posted Date: 2006-12-25

Last Posted Date: 2012-10-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 86

Registration Number: NCT00415675

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Treatment of Resectable Malignant Brain Tumors

Phase 4

Terminated

Conditions: Brain Tumor

Interventions: Device: GliaSite Radiation Therapy System

First Posted Date: 2006-12-25

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00415467

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
Acute Myelogenous Leukemia

Interventions: Drug: Decitabine
Drug: Valproic Acid

First Posted Date: 2006-12-21

Last Posted Date: 2019-05-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 153

Registration Number: NCT00414310

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma

Phase 2

Terminated

Conditions: Leiomyosarcoma
Uterine Neoplasm

Interventions: Drug: Letrozole

First Posted Date: 2006-12-21

Last Posted Date: 2018-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT00414076

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

Phase 2

Completed

Conditions: Acute Promyelocytic Leukemia

Interventions: Drug: All-Trans Retinoic Acid (ATRA)
Drug: Arsenic Trioxide (ATO)
Drug: Idarubicin
Drug: Gemtuzumab Ozogamicin

First Posted Date: 2006-12-19

Last Posted Date: 2019-05-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 78

Registration Number: NCT00413166

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy